| Species |
Human |
| Protein Construction |
CCR8 (Met1-Lys35)
Accession # P51685-1 |
mFc (IgG1) |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized CCR8 mFc Chimera, Human at 1μg/ml (100μl/well) on the plate can bind AntiCCR8 Antibody, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
30.25 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 40-50 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
CC chemokine receptor (CCR) 8 (previously called CKR-L1 or TER1 and designated CD198), which is expressed on Th2 cells and eosinophils, has been implicated in allergic diseases. CCR8 may regulate monocyte chemotaxis and thymic cell line apoptosis and is alternative coreceptor with CD4 for HIV-1 infection. |
| Synonyms |
CCR-8; CMKBRL2; CKR-L1; GPR-CY6; GPRCY6; TER1; CCR8; CKRL1; CMKBR8; CD198; ChemR1; CKR-L1; CY6; TER-1; CDw198 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
